文献速递血脂与心血管预防心力衰竭与心肌病

COVID-19 mRNA疫苗相关心肌炎

Myocarditis With COVID-19 mRNA Vaccines.
PubMed 文献 · Circulation · 2021-07-20

心肌炎是COVID-19 mRNA疫苗接种的罕见并发症,尤其在年轻成年和青少年男性中。美国CDC数据显示,12至39岁人群第二剂mRNA疫苗心肌炎/心包炎发生率约为每百万剂12.6例。患者多在第二剂后2至3天出现胸痛、心肌肌钙蛋白升高、心电图ST段抬高和心脏MRI提示心肌炎,几乎全部患者症状和体征缓解,获益风险评估显示所有年龄和性别组均 favorable,建议12岁以上人群接种。

要点

  • 年轻男性第二剂mRNA疫苗后2-3天出现胸痛需警惕心肌炎。
  • 心肌炎表现为肌钙蛋白升高、心电图ST段抬高和心脏MRI异常。
  • 绝大多数患者症状和诊断指标可缓解,疫苗接种获益仍大于风险。

核心结论

  • COVID-19 mRNA疫苗接种与罕见心肌炎相关,但获益风险评估显示所有年龄和性别组均 favorable,推荐12岁以上人群接种。

研究设计与样本

  • 基于美国CDC监测数据及病例报告的综述性分析,涉及12至39岁人群第二剂mRNA疫苗后心肌炎/心包炎发生率≈12.6例/百万剂。

主要发现

  • 心肌炎患者通常表现为胸痛,多在第二剂mRNA疫苗接种后2至3天出现,并伴有心肌肌钙蛋白水平升高。
  • 大多数患者心电图异常伴ST段抬高,所有接受心脏MRI检查的患者均提示心肌炎。
  • 无急性COVID-19或其他病毒感染证据;1例心肌病基因panel阴性,但自身抗体水平和自然杀伤细胞频率增加。
  • 几乎所有患者症状和体征缓解,诊断标志物和影像学改善,无论是否治疗。

关键数值与推荐

  • 12至39岁人群第二剂mRNA疫苗心肌炎/心包炎发生率≈12.6例/百万剂。
  • 患者通常在第二剂后2至3天出现胸痛,伴心肌肌钙蛋白升高。

临床怎么用

  • 接种mRNA疫苗后年轻男性出现胸痛应评估心肌炎,检查心电图、心肌肌钙蛋白和心脏MRI。
  • 多数心肌炎患者预后良好,支持症状和诊断指标可缓解。
  • 尽管存在罕见心肌炎风险,获益风险评估支持12岁以上人群接种COVID-19疫苗。

局限性

  • 心肌炎发生机制尚不明确,男性 predominance 原因未知,可能涉及性激素差异和女性心脏病诊断不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myocarditis has been recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccinations, especially in young adult and adolescent males. According to the US Centers for Disease Control and Prevention, myocarditis/pericarditis rates are ≈12.6 cases per million doses of second-dose mRNA vaccine among individuals 12 to 39 years of age. In reported cases, patients with myocarditis invariably presented with chest pain, usually 2 to 3 days after a second dose of mRNA vaccination, and had elevated cardiac troponin levels. ECG was abnormal with ST elevations in most, and cardiac MRI was suggestive of myocarditis in all tested patients. There was no evidence of acute COVID-19 or other viral infections. In 1 case, a cardiomyopathy gene panel was negative, but autoantibody levels against certain self-antigens and frequency of natural killer cells were increased. Although the mechanisms for development of myocarditis are not clear, molecular mimicry between the spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and self-antigens, trigger of preexisting dysregulated immune pathways in certain individuals, immune response to mRNA, and activation of immunologic pathways, and dysregulated cytokine expression have been proposed. The reasons for male predominance in myocarditis cases are unknown, but possible explanations relate to sex hormone differences in immune response and myocarditis, and also underdiagnosis of cardiac disease in women. Almost all patients had resolution of symptoms and signs and improvement in diagnostic markers and imaging with or without treatment. Despite rare cases of myocarditis, the benefit-risk assessment for COVID-19 vaccination shows a favorable balance for all age and sex groups; therefore, COVID-19 vaccination is recommended for everyone ≥12 years of age.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bozkurt B, Kamat I, Hotez PJ, et al. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021. PMID: 34281357. doi:10.1161/CIRCULATIONAHA.121.056135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。